Loading...
Loading...
Cyclacel Pharmaceuticals, Inc.
CYCCCYCCP (Cyclacel or the
Company), today announced that scientists at Newcastle University have been
awarded £1 million (approximately $1.5 million) by the UK's Medical Research
Council for a clinical trial to evaluate whether seliciclib, Cyclacel's oral
cyclin dependent kinase (CDK) inhibitor currently in clinical development to
treat certain cancers, can be repurposed to treat rheumatoid arthritis (RA) in
patients who do not respond to existing treatments. Seliciclib may work for RA
by targeting proliferating fibroblasts, a different type of approach than
conventional RA therapies, and could therefore succeed where these treatments
have failed.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in